

GRAM POSITIVE COCCI Percent Susceptible		<i>Enterococcus</i>	<i>Staphylococcus aureus</i>	<i>Staphylococcus coagulase negative</i>	<i>Streptococcus pneumoniae</i>
Number of isolates		1121	1543	1463	109
CLSI -1	Oxacillin		54	37	
	Penicillin		10	11	61
	Cefazolin		54	37	
	Erythromycin		42	34	
	Clindamycin		56	49	
	Trimethoprim/sulfa		98		
	Ampicillin	79			
CLSI -2	Tetracycline		96	84	
	Vancomycin	81	100	100	
	Rifampin (note B)		99		
CLSI -3	Levofloxacin		56	42	
	Moxifloxacin (note A)		86		
	Gentamicin		99	81	
CLSI -4	(Urines only)				
	Nitrofurantoin	78	99	97	
	Levofloxacin	51			

Note A: Moxifloxacin tested on methicillin-susceptible *Staphylococcus aureus* only.

Note B: Rifampin should not be used alone for antimicrobial therapy..

NOTES:

This report summarizes all tested antibiotics, but actual patient reports selectively exclude some susceptibility results.



ALLINA.
MEDICAL
LABORATORIES

800 East 28th Street
Minneapolis, MN 55407-3799
612-863-4000

2007

Outpatient Antimicrobial Susceptibilities of Major Pathogens

The intent of this card is to provide a preliminary **guide** to susceptibilities. This information should be used together with the specific susceptibility results of the isolated organism and guidelines from current publications.

Results are from Allina Medical Laboratories Reference Lab clients and Abbott Northwestern, Mercy, United, and Unity Hospitals outpatient clinics and emergency departments.

All intermediate (I) interpretations are included in the resistant category.

Results include only one isolate per patient.

MRSA and VRE surveillance culture isolates are not included.

All organisms identified are held for a period of 7 days after the final results have been reported, in case further testing is requested. Blood culture isolates are held for 1 month. Testing of additional antimicrobials is available upon request.

For further information, contact:

Jo-Ellen Abraham, Microbiology Technical Consultant/
Manager, JoEllen.Abraham@allina.com; 612-863-8396

James Strom, MD, Pathologist, 612-863-4636



ALLINA.
MEDICAL
LABORATORIES

ALLINA MEDICAL LABORATORIES OUTPATIENTS–2007 ANTIMICROBIAL SUSCEPTIBILITIES

GRAM NEGATIVE BACILLI Percent Susceptible		<i>Citrobacter freundii</i>	<i>Citrobacter koseri</i>	<i>Enterobacter aerogenes</i>	<i>Enterobacter cloacae</i>	<i>Escherichia coli</i>	<i>Klebsiella oxytoca</i>	<i>Klebsiella pneumoniae</i>	<i>Morganella morganii</i>	<i>Proteus mirabilis</i>	<i>Serratia marcescens</i>
Number of isolates		100	29	68	224	1745	134	555	59	208	104
CLSI -1	Ampicillin	0	0*	0	0	59	0	0	0	90	0
	Cefazolin	0	100*	0	0	90	60	95	0	94	0
	Gentamicin	96	100*	100	94	91	99	98	90	95	100
	Tobramycin	98	100*	100	94	93	99	98	98	96	97
CLSI -2	Trimethoprim/sulfa	87	97*	100	91	81	95	94	78	86	100
	Ampicillin/sulbactam	0	0*	0	0	66	78	90	0	92	0
	Piperacillin/tazobactam			85	85	99	92	99	97	100	99
	Cefepime	100	100*	100	99	97	99	96	98	98	100
	Ceftriaxone	79	100*	84	80	97	95	96	98	97	100
	Ceftizoxime	78	100*	67	74	96	96	96	96	98	99
	Ciprofloxacin	85	100*	94	89	80	96	96	83	80	92
	Imipenem	100	100*	100	100	100	100	100			97
	CLSI -3	Ceftazidime	79	100*	82	80	96	99	97	90	98
Aztreonam		85	100*	84	81	97	93	97	100	98	100
CLSI -4	(Urines only)										
	Nitrofurantoin	91	81*	11	36	96	82	33	0	0	0*

GRAM NEGATIVE BACILLI Percent Susceptible		<i>Pseudomonas aeruginosa</i>	<i>Stenotrophomonas maltophilia</i>	<i>Acinetobacter species</i>
Number of isolates		466	83	41
CLSI -1	Ceftazidime	87		51
	Gentamicin	90		90
	Tobramycin	96		93
	Ciprofloxacin			83
	Imipenem			95
	Trimethoprim/sulfa		99	
CLSI -2	Ceftazidime		28	
	Cefepime	89		
	Imipenem	90		
	Levofloxacin		87	
	Ciprofloxacin	78		
	Piperacillin/tazobactam	97		
	Ticarcillin/clavulanate		31	
	Trimethoprim/sulfa			88

Guide for Clinical and Laboratory Standards Institute (CLSI) groupings:

- CLSI -1 Test and report
(First choice drugs for treatment)
- CLSI -2 Test and report selectively.
(Second choice drugs)
- CLSI -3 Use ONLY if institution harbors endemic resistant strains, or for treatment of unusual organisms.
- CLSI -4 For urinary tract only.

*Low number tested; less statistical validity.